17
Participants
Start Date
May 21, 2019
Primary Completion Date
October 7, 2020
Study Completion Date
December 21, 2020
RVT-1401
Subcutaneous administration of RVT-1401
Placebo
Subcutaneous administration of Placebo
Hospital for Special Surgery, New York
Dent Institute, Amherst
Allegheny Neurological Associates, Pittsburgh
Rare Disease Research, Atlanta
Neurological Services of Orlando, Orlando
IMC/Diagnostic and Medical Clinic, Mobile
University of Minnesota - Department of Neurology, Minneapolis
UTSW James W. Aston Ambulatory Care Center - Neurology Clinic, Dallas
CSNA, Colorado Springs
Phoenix Neurological Associates, Phoenix
Care Access Research, Pasadena
The Neurology Center of Southern California, Carlsbad
UC Irvine - MDA ALS and Neuromuscular Center, Orange
Yale School of Medicine Department of Neurology, New Haven
University of Buffalo, Buffalo
University of Alberta Hospitals - Division of Pulmonary Medicine, Edmonton
London Health Sciences Centre, London
Ottawa Hospital Research Institute, Ottawa
University Health Network Toronto General Hospital, Toronto
Montreal Neurological Institute and Hospital, Montreal
Lead Sponsor
Immunovant Sciences GmbH
INDUSTRY